9th Annual Biomarkers Congress
44th Annual New York Cardiovascular Symposium: Major Topics in Cardiology Today
Hilton New York
1335 Avenue of the Americas, New York, NY 10019-6078
New York, New York City
http://www.cardiosource.org/Certified-Education/Courses-and-Conferences/2011/December-2011/New-York-Symposium.aspx
Cardiovascular disease accounts for 17 million annual deaths globally, according to the World Health Organization. With cardiovascular incidents on the rise worldwide, healthcare professionals who manage, treat and assist in the prevention of heart disease require continuous medical insight and feedback in order to impact and improve patient outcomes. The American College of Cardiology responds to this need by providing the premier New York Cardiovascular Symposium.

The ever-popular New York Cardiovascular Symposium examines this year’s latest advances in the management and treatment of cardiovascular disease (CVD). Healthcare professionals from around the world converge during this three-day conference, which highlights current methods and technologies used to treat CVD. Once again, Program Director, Valentin Fuster, MD, PhD, MACC, has selected renowned experts in the field to discuss and debate cutting-edge issues that impact the profession and its practice. Highlighted topics include essentials such as coronary artery and valvular heart diseases, cardiac and electrical failure, and atrial fibrillation. Keep up with current news and best practices in cardiology; don’t miss this significant and highly anticipated event!

Learner Objectives
By projecting how we practice cardiovascular medicine in the next five years, the overall goal of this program is to enhance competency by providing its participants with the most up-to-date developments in the diagnosis, treatment and management of cardiovascular disease and to facilitate this transfer of knowledge into practice to improve patient outcomes.  

Upon completion of this program, attendees should be able to —

    * Debate the new understanding of methods, technologies and timing of treatment for acute coronary syndromes
    * Incorporate current and emerging clinical evidence in the comprehensive assessment, treatment and management of patients with, or at increased risk of, cardiovascular disease including hypertension, diabetes and obesity
    * Critically evaluate antithrombotic therapies for the prevention and management of the various cardiovascular conditions such as coronary artery disease, stroke, valvular heart disease and atrial fibrillation
    * Evaluate and employ contemporary approaches, treatment and management strategies in patients with systolic and diastolic heart failure and rhythm disorders (including atrial and ventricular arrhythmias)
    * Implement evidence-based, evolving approaches for the medical and surgical management of valvular heart disease
    * Outline the 2011 advances in genetics, cell regeneration and molecular signaling that aid in maintaining cardiovascular health as well as evolving diagnostic and therapeutic approaches 

http://www.cardiosource.org/Certified-Education/Courses-and-Conferences/2011/December-2011/New-York-Symposium.aspx

Schedule of Presentations:

Friday, December 9, 2011
06:00:00 Registration | Continental Breakfast
07:15:00 Introductions Andrew Van Tosh, David R. Holmes, Jack Lewin
07:25:00 Coronary Artery Disease — Challenges in 2011 | Session I | New Discoveries in Athero-thrombogenesis, Technologies and Agents
07:30:00 Prediction of Six Upcoming Clinical Trends for the Decade, Based in Three Evolving Tools | Imaging, Genetics and Cell Regeneration
08:00:00 Endothelium, Opening Door for Disease vs. Closing Door for Health: New Insights Into a Battle of Injury by Risk Factors vs. Cell Regeneration
08:25:00 Adventitia Vasa Vasorum and Inflammation | A War in Progress of Defense vs. Betrayal
08:50:00 Panel Discussion
09:20:00 Coffee Break
09:35:00 Session II | Acute Coronary Syndromes
09:40:00 STEMI and NON-STEMI Clock Time Therapy Challenges | The Ambulance, Intervention, Stabilization
10:00:00 STEMI — The Golden First Two Hours | Evolving Therapies Targeted at Myocardial Demand
10:20:00 Antithrombotic Progress — Evolving Oral Agents | ADP Inhibitors, Fr Xa Inhibitors, Thrombin Receptor Blockers
10:40:00 Pharmacogenomics of Clopidogrel, Coumadin and Statins | A So-called “Personalized Medicine”, But Where Is the Data?
10:50:00 A View from a Trialist and Guideland’s Expert
11:00:00 A View from a Pioneer in the Field
11:10:00 Need for New Antithrombotic or Combinations? Role of IT and Stakeholders (FDA, NHLBI, Industry)
11:30:00 Panel Discussion
12:15:00 Lunch
13:10:00 Session III | Chronic Coronary and Systemic Arterial Disease
13:15:00 Athero-thrombosis as a Silent Systemic Disease — The HRP Study | Can Early Detection by Imaging Trigger a Change in Lifestyle?
13:35:00 Athero-thrombosis as a Symptomatic Complex CAD and/or CVD | Similar Management Based on Anatomy, Flow and Co-morbidities
13:55:00 Peripheral Vascular Disease Below the Diaphragm | Can a Medical/Interventional/Surgical Team Work Together?
14:15:00 Refractory Angina/Ischemia/Dyspnea in the Elderly | Evolving Non-interventional Challenges
14:35:00 Panel Discussion
15:05:00 Coffee Break
15:25:00 Session IV | Trends and Challenges of Prevention
15:30:00 Lipids and Evolving Approaches | Further Lowering of LDL-C and Targeting HDL-C?
15:50:00 Hypertension and Evolving Approaches | From Population Salt Reduction to Personalized Treatment Targets
16:15:00 Diabetes and Evolving Approaches | What Are the Contemporary Targets and How to Achieve Them?
16:40:00 Panel Discussion
17:15:00 Adjournment
Saturday, December 10, 2011
06:15:00 Continental Breakfast
06:20:00 Cardiopulmonary and Electrical Failure 2011
06:25:00 Session V | Systolic Heart Failure and Basis for Management
07:00:00 Evolving Diagnostic and Prognostic Imaging (MR, CT) of the Various Cardiomyopathies: Myocarditis, Dilated, Infiltrative (Amyloid, Sarcoid), Hypertrophic, Non-compaction
07:25:00 Biomarker vs. Clinically Guided Heart Failure Care | Systolic vs. Diastolic Dysfunction — Where Are the Gains?
07:45:00 Evolving Role of Cardiac Resynchronization in Cardiac Failure | Systolic Dysfunction, Diastolic Dysfunction, Mitral Regurgitation
08:05:00 Destination LVADs | A Rapidly-evolving Alternative to Heart Transplantation
08:25:00 Trends in Length of Stay, Economics and Tentative Solutions in 2011
08:45:00 State-of-the-Art Management of Pulmonary Hypertension | Based on an Understanding of the Various Etiologies
09:10:00 Panel Discussion
09:50:00 Coffee Break
09:55:00 Session VI | Rhythm Disorders, Contemporary and Future Topics of Focus
10:10:00 Integrating the Continuum of Science — Heart Failure and Sudden Death | An Evolving Challenge for the Elderly
10:30:00 Managing Ventricular Tachycardia | Catheter Ablation and Beyond, Survival Free from ICD Therapy
10:50:00 State-of-the-Art and Evolving Understanding of Atrial Fibrillation | Approach to Quality of Life (Rate/Rhythm and ANSD) and Clots
11:15:00 Catheter Ablation in Atrial Fibrillation | When, How, Present Data and Future Expectations
11:35:00 Panel Discussion
12:00:00 Lunch
12:10:00 Present Understanding/Management of HCM and Non-compaction LV | Systolic and Diastolic Pharmacological Approach, Antithrombotic? IHSS — When Septal Reduction (Alcohol, Myectomy)? AICD?
12:50:00 Valvular Heart Disease and Aorta — Challenges in 2011
12:55:00 Session VII | Management of Aortic Valve Disease, IHSS and Aorta
13:00:00 Asymptomatic Severe AS (AVA< 0.75 cm2 or AVVel > 4.5 m/s) and LVH Is It Time for Operation?
13:20:00 The Best Aortic Prosthetic Valve Choice for a 45-year-old | Mechanic? Pericardial (TAVI Later if Degenerates)? Ross Procedure?
13:40:00 The Best Procedure of Choice for a 70- to 80-year-old? Evolving Approaches to TAVI, Including Stroke Prevention
13:50:00 The Interventionalist Perspective
14:00:00 The Surgeon Perspective
14:35:00 Asymptomatic or Symptomatic Severe AR | It’s Never Too Early or Too Late for AVR
14:55:00 The Dilated Aorta and Complicating Dissection | New Understanding of the Basic Biology and Evolving Management
15:15:00 Panel Discussion
15:35:00 Coffee Break
15:50:00 Session VIII | Management of Mitral Regurgitation
15:55:00 It May Be Too Early or Too Late for Surgery in Severe Mitral Regurgitation
16:15:00 What a Cardiologist Needs to Know About MR in 2012
16:35:00 Future of Percutaneous Devices for Mitral Regurgitation | MitraClip? Coronary Sinus? Percutaneous Remodeling or MVR?
16:55:00 Panel Discussion
17:15:00 Adjournment
Sunday, December 11, 2011
06:30:00 Continental Breakfast
07:25:00 Session IX | Novelties on Genetics, Cell Regeneration and Molecular Signaling
07:30:00 Embriogenic Development of the Heart | Implications for Stem Cell Regeneration in the Adult Myocardium
07:50:00 Stem Cell Regeneration for the Scarred Adult Myocardium A Therapeutic Response to Islet Progenitor Cells and Paracrine Factors
08:10:00 Stem Cell-based Heart Replacement Status of the Taylor Heart
08:30:00 The Early Human Experience of Gene Therapy in Heart Failure | “Revitalizing the Viable Myocardium”
08:45:00 Section X | Novelties on Diagnostic and Therapeutic Strategies
09:10:00 Poly-imaging for Early Myocardial Disease Identification and Management
09:30:00 Renal Sympathetic Denervation | Applications in Hypertension and Beyond
09:50:00 HENRY I RUSSEK LECTURE 2011 | Vascular Cognitive Mechanisms and Diagnosis
10:20:00 Coffee Break
10:35:00 Section XI | The Future Extremes of Cardiovascular Medicine
10:40:00 In a World of Economic Restraint, Ambulatory PCI? Is It Safe for All?
11:00:00 Promoting Cardiovascular Health Worldwide A Start with Demonstration Projects in the Community?
11:20:00 PAUL DUDLEY WHITE LECTURE 2011 | The Art of Clinical Trials in Health and Disease Triumphs and Fallacies
11:50:00 Next Year’s Innovations
12:00:00 Program Adjournment
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.